Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Iran | 122 | 2024 | 736 | 7.260 |
Why?
|
Prediabetic State | 9 | 2024 | 546 | 2.710 |
Why?
|
Cardiovascular Diseases | 54 | 2024 | 15520 | 2.670 |
Why?
|
Diabetes Mellitus, Type 2 | 41 | 2024 | 12159 | 2.140 |
Why?
|
Glucose Intolerance | 4 | 2023 | 575 | 2.010 |
Why?
|
Diabetes Mellitus | 18 | 2024 | 5842 | 1.620 |
Why?
|
Glucose | 22 | 2024 | 4342 | 1.520 |
Why?
|
Lipids | 34 | 2024 | 3331 | 1.470 |
Why?
|
Blood Glucose | 33 | 2024 | 6392 | 1.280 |
Why?
|
Congenital Hypothyroidism | 4 | 2021 | 40 | 1.200 |
Why?
|
Hypertension | 19 | 2023 | 8536 | 0.980 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2024 | 3245 | 0.970 |
Why?
|
Life Style | 6 | 2020 | 3907 | 0.890 |
Why?
|
Risk Factors | 82 | 2024 | 74239 | 0.830 |
Why?
|
Waist Circumference | 15 | 2024 | 933 | 0.800 |
Why?
|
Coronary Disease | 8 | 2018 | 5921 | 0.700 |
Why?
|
Primary Prevention | 2 | 2024 | 1185 | 0.660 |
Why?
|
Incidence | 39 | 2024 | 21365 | 0.620 |
Why?
|
Health Education | 3 | 2020 | 1049 | 0.610 |
Why?
|
Adult | 104 | 2024 | 221119 | 0.600 |
Why?
|
Female | 131 | 2024 | 392544 | 0.590 |
Why?
|
Risk Assessment | 25 | 2024 | 24021 | 0.590 |
Why?
|
Body Mass Index | 26 | 2024 | 12952 | 0.570 |
Why?
|
Middle Aged | 88 | 2024 | 220853 | 0.560 |
Why?
|
Hashimoto Disease | 3 | 2024 | 107 | 0.550 |
Why?
|
Male | 108 | 2024 | 360693 | 0.530 |
Why?
|
Humans | 164 | 2024 | 761208 | 0.530 |
Why?
|
Decision Trees | 2 | 2014 | 505 | 0.520 |
Why?
|
Polycystic Ovary Syndrome | 4 | 2020 | 376 | 0.480 |
Why?
|
Sex Factors | 14 | 2024 | 10553 | 0.450 |
Why?
|
American Heart Association | 2 | 2018 | 1043 | 0.450 |
Why?
|
Cholesterol, HDL | 7 | 2024 | 1812 | 0.450 |
Why?
|
Data Mining | 2 | 2015 | 554 | 0.440 |
Why?
|
Selection Bias | 1 | 2014 | 359 | 0.420 |
Why?
|
Metabolic Diseases | 1 | 2019 | 680 | 0.410 |
Why?
|
Follow-Up Studies | 32 | 2024 | 39126 | 0.410 |
Why?
|
Triglycerides | 9 | 2024 | 2457 | 0.410 |
Why?
|
Cohort Studies | 27 | 2024 | 41496 | 0.410 |
Why?
|
Diabetes, Gestational | 4 | 2023 | 1250 | 0.410 |
Why?
|
Smoking | 14 | 2023 | 9055 | 0.410 |
Why?
|
Methimazole | 2 | 2024 | 41 | 0.400 |
Why?
|
Epidemiologic Studies | 1 | 2015 | 677 | 0.400 |
Why?
|
Blood Pressure | 14 | 2024 | 8479 | 0.400 |
Why?
|
Insulin Resistance | 2 | 2023 | 3952 | 0.390 |
Why?
|
Adiposity | 8 | 2024 | 1879 | 0.390 |
Why?
|
Antithyroid Agents | 2 | 2024 | 72 | 0.390 |
Why?
|
Neonatal Screening | 4 | 2021 | 597 | 0.390 |
Why?
|
Population Surveillance | 4 | 2021 | 2598 | 0.390 |
Why?
|
Middle East | 3 | 2022 | 231 | 0.390 |
Why?
|
Death Certificates | 1 | 2012 | 168 | 0.370 |
Why?
|
Accidents | 1 | 2012 | 165 | 0.370 |
Why?
|
Aged | 46 | 2024 | 169288 | 0.360 |
Why?
|
Exercise | 5 | 2021 | 5874 | 0.360 |
Why?
|
Health Personnel | 2 | 2022 | 3337 | 0.350 |
Why?
|
Obesity | 17 | 2024 | 12939 | 0.350 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2021 | 2254 | 0.350 |
Why?
|
Graves Disease | 2 | 2024 | 238 | 0.340 |
Why?
|
Menarche | 2 | 2024 | 532 | 0.330 |
Why?
|
Proportional Hazards Models | 16 | 2021 | 12474 | 0.330 |
Why?
|
Weight Gain | 5 | 2024 | 2349 | 0.330 |
Why?
|
Dyslipidemias | 4 | 2024 | 870 | 0.320 |
Why?
|
Health Status | 4 | 2021 | 4077 | 0.320 |
Why?
|
Interleukins | 1 | 2013 | 782 | 0.310 |
Why?
|
Prospective Studies | 30 | 2024 | 54435 | 0.310 |
Why?
|
Premenstrual Syndrome | 2 | 2020 | 109 | 0.310 |
Why?
|
Mass Screening | 3 | 2020 | 5426 | 0.300 |
Why?
|
Angina Pectoris | 1 | 2012 | 959 | 0.300 |
Why?
|
Obesity, Abdominal | 2 | 2023 | 373 | 0.300 |
Why?
|
Cholesterol | 7 | 2024 | 2902 | 0.290 |
Why?
|
Minority Groups | 1 | 2014 | 1201 | 0.280 |
Why?
|
Young Adult | 34 | 2024 | 59221 | 0.280 |
Why?
|
Prehypertension | 2 | 2019 | 63 | 0.280 |
Why?
|
Urban Population | 4 | 2021 | 2036 | 0.270 |
Why?
|
Models, Theoretical | 2 | 2015 | 3571 | 0.270 |
Why?
|
Longitudinal Studies | 10 | 2023 | 14610 | 0.270 |
Why?
|
Anthropometry | 3 | 2020 | 1338 | 0.260 |
Why?
|
Glucose Tolerance Test | 3 | 2023 | 1178 | 0.250 |
Why?
|
Area Under Curve | 3 | 2020 | 1636 | 0.240 |
Why?
|
Prevalence | 14 | 2024 | 15721 | 0.240 |
Why?
|
Forecasting | 4 | 2020 | 2928 | 0.240 |
Why?
|
Thyroxine | 4 | 2021 | 665 | 0.230 |
Why?
|
Hypothyroidism | 2 | 2020 | 668 | 0.230 |
Why?
|
Cardiology | 1 | 2015 | 1693 | 0.220 |
Why?
|
Income | 2 | 2024 | 1869 | 0.220 |
Why?
|
Age Factors | 9 | 2024 | 18384 | 0.220 |
Why?
|
Hepatitis C | 1 | 2013 | 1579 | 0.220 |
Why?
|
Estrogens | 2 | 2021 | 1522 | 0.220 |
Why?
|
Cause of Death | 2 | 2023 | 3688 | 0.210 |
Why?
|
Thyroid Gland | 2 | 2020 | 1169 | 0.210 |
Why?
|
Knowledge | 1 | 2024 | 178 | 0.200 |
Why?
|
Logistic Models | 10 | 2021 | 13249 | 0.190 |
Why?
|
Fabaceae | 1 | 2022 | 103 | 0.190 |
Why?
|
Gastric Bypass | 2 | 2022 | 818 | 0.190 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7400 | 0.190 |
Why?
|
Disease Progression | 6 | 2024 | 13511 | 0.190 |
Why?
|
Iodide Peroxidase | 1 | 2023 | 294 | 0.190 |
Why?
|
Echium | 1 | 2020 | 3 | 0.190 |
Why?
|
Contraceptives, Oral | 2 | 2020 | 554 | 0.180 |
Why?
|
Body Weights and Measures | 2 | 2019 | 208 | 0.180 |
Why?
|
Asymptomatic Diseases | 1 | 2024 | 588 | 0.180 |
Why?
|
Diet | 7 | 2022 | 8048 | 0.180 |
Why?
|
Pregnancy in Diabetics | 1 | 2022 | 197 | 0.180 |
Why?
|
Cross-Sectional Studies | 13 | 2023 | 26071 | 0.170 |
Why?
|
Thyroid Function Tests | 1 | 2021 | 288 | 0.170 |
Why?
|
Thyrotropin | 2 | 2021 | 833 | 0.170 |
Why?
|
Levonorgestrel | 1 | 2020 | 74 | 0.170 |
Why?
|
Sulfonylurea Compounds | 1 | 2021 | 219 | 0.170 |
Why?
|
Rural Population | 2 | 2021 | 2277 | 0.170 |
Why?
|
Africa, Northern | 1 | 2019 | 86 | 0.170 |
Why?
|
Electrocardiography | 2 | 2012 | 6387 | 0.170 |
Why?
|
Time Factors | 14 | 2024 | 39957 | 0.160 |
Why?
|
Prognosis | 12 | 2024 | 29687 | 0.160 |
Why?
|
Weight Loss | 4 | 2024 | 2680 | 0.160 |
Why?
|
Obesity, Morbid | 2 | 2022 | 1277 | 0.160 |
Why?
|
Hypoglycemic Agents | 2 | 2022 | 3089 | 0.160 |
Why?
|
Waist-Hip Ratio | 5 | 2023 | 518 | 0.160 |
Why?
|
Bayes Theorem | 4 | 2024 | 2329 | 0.160 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2020 | 116 | 0.160 |
Why?
|
History of Medicine | 1 | 2019 | 42 | 0.160 |
Why?
|
Quality of Life | 4 | 2021 | 13367 | 0.160 |
Why?
|
Dietary Supplements | 2 | 2024 | 3410 | 0.160 |
Why?
|
Acromegaly | 1 | 2021 | 310 | 0.150 |
Why?
|
Phytotherapy | 1 | 2020 | 296 | 0.150 |
Why?
|
Amides | 1 | 2021 | 449 | 0.150 |
Why?
|
Fetal Macrosomia | 3 | 2023 | 138 | 0.150 |
Why?
|
Vitamin D | 2 | 2024 | 3301 | 0.150 |
Why?
|
Sarcopenia | 1 | 2023 | 370 | 0.150 |
Why?
|
Socioeconomic Factors | 3 | 2019 | 7804 | 0.140 |
Why?
|
Australia | 1 | 2021 | 1246 | 0.140 |
Why?
|
Nutritive Value | 1 | 2020 | 347 | 0.140 |
Why?
|
Sex Characteristics | 2 | 2019 | 2640 | 0.140 |
Why?
|
Multivariate Analysis | 6 | 2017 | 12052 | 0.140 |
Why?
|
Odds Ratio | 7 | 2019 | 9652 | 0.140 |
Why?
|
Overweight | 3 | 2022 | 2418 | 0.140 |
Why?
|
Plant Extracts | 1 | 2020 | 496 | 0.140 |
Why?
|
Gastrectomy | 2 | 2022 | 671 | 0.140 |
Why?
|
Infant, Newborn, Diseases | 1 | 2022 | 589 | 0.140 |
Why?
|
Cluster Analysis | 2 | 2021 | 2706 | 0.140 |
Why?
|
Human Growth Hormone | 1 | 2021 | 642 | 0.130 |
Why?
|
Thyroid Hormones | 1 | 2019 | 402 | 0.130 |
Why?
|
Probability | 1 | 2021 | 2478 | 0.130 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2021 | 4014 | 0.130 |
Why?
|
Menstruation Disturbances | 1 | 2017 | 143 | 0.130 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1385 | 0.130 |
Why?
|
Decision Support Techniques | 2 | 2024 | 2004 | 0.130 |
Why?
|
Uterine Hemorrhage | 1 | 2017 | 240 | 0.130 |
Why?
|
Lipoproteins, HDL | 2 | 2023 | 675 | 0.130 |
Why?
|
Family Health | 1 | 2020 | 1254 | 0.130 |
Why?
|
Aging | 1 | 2014 | 8702 | 0.120 |
Why?
|
Iodine | 1 | 2017 | 285 | 0.120 |
Why?
|
Habits | 1 | 2016 | 147 | 0.120 |
Why?
|
Models, Statistical | 3 | 2021 | 5081 | 0.120 |
Why?
|
Drug Prescriptions | 1 | 2024 | 1668 | 0.120 |
Why?
|
Pyrazines | 1 | 2021 | 1202 | 0.120 |
Why?
|
Cold Temperature | 1 | 2019 | 783 | 0.120 |
Why?
|
Educational Status | 2 | 2020 | 2510 | 0.120 |
Why?
|
Wrist | 2 | 2014 | 226 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2023 | 2455 | 0.120 |
Why?
|
History, 21st Century | 1 | 2020 | 1567 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15920 | 0.110 |
Why?
|
Nutritional Status | 2 | 2019 | 1597 | 0.110 |
Why?
|
Cardiovascular System | 2 | 2019 | 836 | 0.110 |
Why?
|
Infant, Newborn | 7 | 2023 | 26199 | 0.110 |
Why?
|
Calcium | 2 | 2024 | 5719 | 0.110 |
Why?
|
Recurrence | 2 | 2024 | 8457 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2023 | 2864 | 0.110 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1233 | 0.110 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1791 | 0.110 |
Why?
|
Adolescent | 15 | 2024 | 88298 | 0.110 |
Why?
|
Food Preferences | 1 | 2017 | 398 | 0.110 |
Why?
|
ROC Curve | 2 | 2019 | 3584 | 0.110 |
Why?
|
Death, Sudden, Cardiac | 1 | 2021 | 1560 | 0.110 |
Why?
|
Osteoporosis | 1 | 2023 | 1604 | 0.110 |
Why?
|
Coronary Artery Disease | 3 | 2024 | 6505 | 0.110 |
Why?
|
Pituitary Neoplasms | 1 | 2021 | 1322 | 0.100 |
Why?
|
Health Surveys | 4 | 2021 | 4037 | 0.100 |
Why?
|
Arabs | 1 | 2015 | 187 | 0.100 |
Why?
|
Energy Intake | 1 | 2020 | 2133 | 0.100 |
Why?
|
Glucose Metabolism Disorders | 1 | 2012 | 52 | 0.100 |
Why?
|
Bariatric Surgery | 1 | 2022 | 991 | 0.100 |
Why?
|
Autoimmunity | 1 | 2020 | 1356 | 0.100 |
Why?
|
Asia | 2 | 2024 | 622 | 0.100 |
Why?
|
Hot Temperature | 1 | 2019 | 1434 | 0.100 |
Why?
|
Chi-Square Distribution | 3 | 2015 | 3418 | 0.100 |
Why?
|
Diabetic Retinopathy | 1 | 2021 | 1276 | 0.100 |
Why?
|
Psychometrics | 1 | 2021 | 3061 | 0.100 |
Why?
|
Program Evaluation | 1 | 2020 | 2489 | 0.100 |
Why?
|
Validation Studies as Topic | 1 | 2012 | 162 | 0.100 |
Why?
|
Retrospective Studies | 9 | 2024 | 80674 | 0.090 |
Why?
|
Sex Distribution | 4 | 2020 | 2277 | 0.090 |
Why?
|
Premature Birth | 1 | 2023 | 1784 | 0.090 |
Why?
|
Adenoma | 1 | 2021 | 2159 | 0.090 |
Why?
|
Residence Characteristics | 1 | 2020 | 2092 | 0.090 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20119 | 0.090 |
Why?
|
Lipid Metabolism | 1 | 2019 | 1893 | 0.090 |
Why?
|
Autoantibodies | 1 | 2019 | 2119 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6486 | 0.090 |
Why?
|
Atherosclerosis | 2 | 2024 | 3406 | 0.090 |
Why?
|
United States | 6 | 2024 | 72339 | 0.090 |
Why?
|
Cost-Benefit Analysis | 1 | 2023 | 5493 | 0.080 |
Why?
|
Predictive Value of Tests | 6 | 2019 | 15308 | 0.080 |
Why?
|
Lipoproteins | 1 | 2014 | 877 | 0.080 |
Why?
|
Infertility, Female | 1 | 2015 | 761 | 0.080 |
Why?
|
Quality Control | 1 | 2012 | 833 | 0.080 |
Why?
|
Neoplasms | 2 | 2022 | 22140 | 0.080 |
Why?
|
National Health Programs | 1 | 2012 | 440 | 0.080 |
Why?
|
Cytokines | 1 | 2024 | 7386 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2021 | 3048 | 0.080 |
Why?
|
Aged, 80 and over | 7 | 2022 | 58952 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2021 | 22174 | 0.080 |
Why?
|
Feeding Behavior | 1 | 2020 | 3183 | 0.080 |
Why?
|
Pregnancy Outcome | 3 | 2023 | 2923 | 0.070 |
Why?
|
Treatment Outcome | 6 | 2024 | 64681 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2021 | 5295 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2672 | 0.070 |
Why?
|
Research Design | 1 | 2023 | 6180 | 0.070 |
Why?
|
Hyperglycemia | 1 | 2016 | 1375 | 0.070 |
Why?
|
Propensity Score | 3 | 2023 | 1916 | 0.070 |
Why?
|
Students | 1 | 2017 | 1737 | 0.070 |
Why?
|
Survival Rate | 4 | 2016 | 12728 | 0.070 |
Why?
|
Fasting | 2 | 2023 | 1603 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2018 | 1847 | 0.070 |
Why?
|
Medical Records | 1 | 2012 | 1409 | 0.070 |
Why?
|
Regression Analysis | 2 | 2015 | 6345 | 0.070 |
Why?
|
False Positive Reactions | 2 | 2019 | 958 | 0.070 |
Why?
|
Sensitivity and Specificity | 3 | 2018 | 14675 | 0.060 |
Why?
|
Pregnancy | 6 | 2023 | 29893 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2820 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2015 | 1457 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2019 | 3417 | 0.060 |
Why?
|
Air Pollution | 1 | 2019 | 2351 | 0.060 |
Why?
|
Stroke | 3 | 2018 | 9721 | 0.060 |
Why?
|
Patient Compliance | 3 | 2020 | 2688 | 0.060 |
Why?
|
Age Distribution | 3 | 2018 | 2871 | 0.060 |
Why?
|
Malaysia | 1 | 2024 | 107 | 0.060 |
Why?
|
Survival Analysis | 1 | 2017 | 10088 | 0.060 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2024 | 92 | 0.060 |
Why?
|
Glomerular Filtration Rate | 3 | 2021 | 2182 | 0.060 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2024 | 127 | 0.060 |
Why?
|
Cesarean Section | 2 | 2023 | 1399 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2011 | 8003 | 0.060 |
Why?
|
Infant | 2 | 2023 | 36169 | 0.060 |
Why?
|
Registries | 2 | 2011 | 8247 | 0.060 |
Why?
|
Universities | 2 | 2020 | 995 | 0.050 |
Why?
|
Cholesterol, LDL | 2 | 2024 | 2380 | 0.050 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2024 | 174 | 0.050 |
Why?
|
Medical Assistance | 1 | 2024 | 108 | 0.050 |
Why?
|
World Health Organization | 1 | 2009 | 1321 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 17897 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2023 | 126 | 0.050 |
Why?
|
Coronary Vessels | 2 | 2024 | 3111 | 0.050 |
Why?
|
Artificial Intelligence | 1 | 2015 | 2576 | 0.050 |
Why?
|
Likelihood Functions | 1 | 2024 | 991 | 0.040 |
Why?
|
Intubation | 1 | 2021 | 139 | 0.040 |
Why?
|
Capsules | 1 | 2020 | 191 | 0.040 |
Why?
|
Epidemiologic Methods | 2 | 2015 | 1336 | 0.040 |
Why?
|
Subcutaneous Fat | 1 | 2023 | 393 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2021 | 399 | 0.040 |
Why?
|
Persia | 1 | 2019 | 7 | 0.040 |
Why?
|
Glycemic Index | 1 | 2022 | 396 | 0.040 |
Why?
|
Referral and Consultation | 2 | 2023 | 3608 | 0.040 |
Why?
|
Withholding Treatment | 1 | 2024 | 616 | 0.040 |
Why?
|
Fatty Acids, Monounsaturated | 1 | 2020 | 190 | 0.040 |
Why?
|
Health Transition | 1 | 2019 | 35 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8530 | 0.040 |
Why?
|
Research Personnel | 1 | 2024 | 588 | 0.040 |
Why?
|
Ritonavir | 1 | 2021 | 329 | 0.040 |
Why?
|
Algorithms | 2 | 2022 | 14025 | 0.040 |
Why?
|
Brain Ischemia | 1 | 2012 | 3032 | 0.040 |
Why?
|
Antihypertensive Agents | 2 | 2019 | 2019 | 0.040 |
Why?
|
Pregnancy Trimester, First | 1 | 2023 | 908 | 0.040 |
Why?
|
History, Ancient | 1 | 2019 | 213 | 0.040 |
Why?
|
Cholecalciferol | 1 | 2024 | 552 | 0.040 |
Why?
|
Reference Values | 2 | 2018 | 4921 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2024 | 12341 | 0.040 |
Why?
|
Child, Preschool | 1 | 2021 | 42224 | 0.040 |
Why?
|
Intra-Abdominal Fat | 1 | 2023 | 612 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6341 | 0.040 |
Why?
|
Internationality | 1 | 2023 | 999 | 0.040 |
Why?
|
Medical Audit | 1 | 2019 | 452 | 0.040 |
Why?
|
Carotid Artery Diseases | 1 | 2024 | 877 | 0.040 |
Why?
|
Systole | 1 | 2019 | 936 | 0.040 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2020 | 550 | 0.040 |
Why?
|
Diastole | 1 | 2019 | 782 | 0.040 |
Why?
|
Heart Failure | 1 | 2021 | 11701 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 426 | 0.030 |
Why?
|
Hip | 1 | 2018 | 255 | 0.030 |
Why?
|
Focus Groups | 1 | 2022 | 1413 | 0.030 |
Why?
|
Pedigree | 1 | 2024 | 4537 | 0.030 |
Why?
|
Behavior | 1 | 2019 | 540 | 0.030 |
Why?
|
Child | 5 | 2024 | 80152 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2024 | 4851 | 0.030 |
Why?
|
Remission Induction | 1 | 2021 | 2392 | 0.030 |
Why?
|
Causality | 1 | 2021 | 1244 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2082 | 0.030 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2015 | 152 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 649 | 0.030 |
Why?
|
Medical History Taking | 1 | 2017 | 773 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2023 | 2691 | 0.030 |
Why?
|
Linear Models | 1 | 2023 | 5869 | 0.030 |
Why?
|
Marital Status | 1 | 2014 | 425 | 0.030 |
Why?
|
Calibration | 1 | 2015 | 819 | 0.030 |
Why?
|
Fatty Acids | 1 | 2020 | 1807 | 0.030 |
Why?
|
Hospitalization | 2 | 2022 | 10707 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1723 | 0.030 |
Why?
|
Diet Surveys | 1 | 2016 | 1161 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 998 | 0.020 |
Why?
|
Qualitative Research | 1 | 2022 | 3024 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2015 | 942 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15841 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2023 | 3313 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2024 | 4372 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6304 | 0.020 |
Why?
|
Premenopause | 1 | 2015 | 1039 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3149 | 0.020 |
Why?
|
Computer Simulation | 1 | 2023 | 6224 | 0.020 |
Why?
|
Comorbidity | 2 | 2016 | 10516 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2015 | 970 | 0.020 |
Why?
|
Social Class | 1 | 2018 | 1993 | 0.020 |
Why?
|
Oxygen | 1 | 2021 | 4227 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4537 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2023 | 12747 | 0.020 |
Why?
|
Down-Regulation | 1 | 2015 | 2916 | 0.020 |
Why?
|
Employment | 1 | 2014 | 1114 | 0.020 |
Why?
|
Parents | 1 | 2021 | 3564 | 0.020 |
Why?
|
Research Report | 1 | 2010 | 367 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6417 | 0.020 |
Why?
|
Reference Standards | 1 | 2010 | 1005 | 0.020 |
Why?
|
Postmenopause | 1 | 2015 | 2514 | 0.020 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2017 | 2517 | 0.020 |
Why?
|
Phenotype | 1 | 2022 | 16575 | 0.010 |
Why?
|
Computational Biology | 1 | 2014 | 3499 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8663 | 0.010 |
Why?
|
Mutation | 1 | 2024 | 30002 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2015 | 10422 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16952 | 0.010 |
Why?
|
Societies, Medical | 1 | 2010 | 3923 | 0.010 |
Why?
|